AT13148

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1/2/3, p70S6K, PKA, and ROCKI/II.

AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 is currently being developed by Astex Pharmaceuticals. AT131148 was identified utilizing high-throughput X-ray crystallography and fragment-based lead discovery techniques. AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK substrate phosphorylation and induction of apoptosis in both a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects both in vitro and in vivo.

AT-13148; AT13148 hydrochloride; AT13148 HCl

Others

Other Targets

Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3

Cancer

——

1056901-62-2

313.78

C17H16ClN3O

97%

DMSO : 50 mg/mL 159.35 mM;

[C@](O)(c1ccc(cc1)Cl)(c1ccc(cc1)c1cn[nH]c1)CN

(S)-1-(4-(1H-pyrazol-4-yl)phenyl)-2-amino-1-(4-chlorophenyl)ethanol

(-20℃)

With Ice Pack

≥ 2 years